Personalized Kampo Medicine Facilitated Both Cytotoxic T Lymphocyte Response and Clinical Benefits Induced by Personalized Peptide Vaccination for Advanced Esophageal Cancer

<div>Biomarker study: analysis of biomarkers predictive of OS time using prevaccination samples. Results for IL-6 (a) and IL-8 (b) and the percentages of lymphocytes (c) are shown. Results of biomarker studies prognostic of OS time using postvaccination samples were shown as follows: IL-6 in (d), BAFF in (e), and neutrophil percentage in (f).</div>

Evidence-Based Complementary and Alternative Medicine

fig4

Figure 4

Figure 4: Personalized Kampo Medicine Facilitated Both Cytotoxic T Lymphocyte Response and Clinical Benefits Induced by Personalized Peptide Vaccination for Advanced Esophageal Cancer 

Figure 4 | Personalized Kampo Medicine Facilitated Both Cytotoxic T Lymphocyte Response and Clinical Benefits Induced by Personalized Peptide Vaccination for Advanced Esophageal Cancer 